Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Rheumatology
•
Hematology
•
General Rheumatology
•
Infectious Disease
•
Gastroenterology
•
Vaccines
•
Immunizations
•
Allergy & Immunology
•
Nephrology
•
Immunosuppression
•
Cardiology
•
Primary Care
What is your approach to RSV vaccination in immunocompromised patients?
Related Questions
In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
Excluding CLL, in which patients would you screen for hypogammaglobulinemia?
Would you offer live vaccines (e.g., MMRV/measles) to patients on bispecific antibodies for multiple myeloma?
In a young patient who was vaccinated to chickenpox as a child (no previous varicella infection) should the patient receive a shingles vaccine prior to starting Rinvoq?
Would you consider anti-IL-5 therapy (mepolizumab or benralizumab) to either prevent or treat the more severe manifestations of eosinophilic granulomatosis with polyangiitis, such as "infiltrative" (e.g., cardiomyopathy, pulmonary infiltrates, or gastroenteritis) or "vasculitic" (e.g., neuropathy, palpable purpura, or glomerulonephritis)?
How do you approach vaccination, particularly the use of live vaccines such as yellow fever, in a patient with rheumatoid arthritis receiving a TNF inhibitor who is planning travel to Africa?
How do you think about using Ropeginterferon Alfa 2B for polycythemia vera in patients with active autoimmune disease?
How do you manage anticoagulation/antiplatelet therapies with strong indications for uninterrupted therapy in setting of urgent procedures?